PTGX Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 20.83%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Johnson & Johnson's return on equity of 33.27%.

Protagonist Therapeutics, Inc. has a consensus price target of $96.33, signalling upside risk potential of 13.61%. On the other hand Johnson & Johnson has an analysts' consensus of $221.54 which suggests that it could grow by 1.4%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Protagonist Therapeutics, Inc. is more attractive than Johnson & Johnson.

Protagonist Therapeutics, Inc. has a beta of 2.260, which suggesting that the stock is 126.048% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.35% to investors and pays a quarterly dividend of $1.30 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Johnson & Johnson's net income of $5.1B. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 133.89x while Johnson & Johnson's PE ratio is 19.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 26.00x versus 5.63x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 81.15%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Protagonist Therapeutics, Inc. has a consensus price target of $96.33, signalling upside risk potential of 13.61%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $276.60 which suggests that it could fall by -4.33%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Protagonist Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..

Protagonist Therapeutics, Inc. has a beta of 2.260, which suggesting that the stock is 126.048% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.705%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 133.89x while Krystal Biotech, Inc.'s PE ratio is 43.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 26.00x versus 23.12x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MannKind Corp. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 9.72%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat MannKind Corp.'s return on equity of --.

Protagonist Therapeutics, Inc. has a consensus price target of $96.33, signalling upside risk potential of 13.61%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 62.63%. Given that MannKind Corp. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc. has a beta of 2.260, which suggesting that the stock is 126.048% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.55%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than MannKind Corp.'s net income of $8M. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 133.89x while MannKind Corp.'s PE ratio is 62.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 26.00x versus 5.81x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 38.89%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Protagonist Therapeutics, Inc. has a consensus price target of $96.33, signalling upside risk potential of 13.61%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $830.04 which suggests that it could grow by 9.87%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Protagonist Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Protagonist Therapeutics, Inc. has a beta of 2.260, which suggesting that the stock is 126.048% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.88 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 133.89x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 26.00x versus 5.84x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.